Circulation, Vol 87, 1093-1099, Copyright © 1993 by American Heart Association
P Sogaard, CO Gotzsche, J Ravkilde and K Thygesen
BACKGROUND. Treatment with angiotensin converting enzyme inhibitors has
been shown to be beneficial in patients with heart failure and myocardial
infarction. Experimental studies have shown beneficial effects on the
ischemic myocardium. METHODS AND RESULTS. The effects of captopril were
evaluated in 64 patients with left ventricular dysfunction after myocardial
infarction. The patients were randomized at day 7 to either placebo or
captopril (50 mg daily) in a double-blind parallel study over a period of 6
months. The patients were followed up by means of ambulatory ECG
monitoring, bicycle ergometer testing, and echocardiographic examination.
The duration of ST segment depression detected during ambulatory ECG
monitoring was lower in the captopril group (87 minutes) than in the
placebo group (638 minutes) (p < 0.001), and the number of patients in
the captopril group with exercise-induced ST segment depression (p <
0.01) was lower at the completion of the study. The working capacity
increased during the study period from 540 +/- 47 seconds to 738 +/- 41
seconds (p < 0.01) in the captopril group and was higher than that in
the placebo group (530 +/- 43 seconds, p < 0.01) at the end of the
study. Furthermore, a significant dilation of the left ventricular
end-diastolic and end-systolic volumes was observed in the placebo group (p
< 0.05); this was prevented in the captopril group where, in addition, a
reduction in end-systolic volume was observed (p < 0.05). CONCLUSIONS.
Captopril has a favorable effect on the dysfunctioning myocardium after
myocardial infarction inasmuch as the ischemic burden is reduced, the
working capacity is increased, dilation of the left ventricle is prevented,
and systolic function is improved.
ARTICLES
Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction
Department of Medicine and Cardiology, Aarhus University Hospital, Denmark.
This article has been cited by other articles:
![]() |
J. Abdulla, S. Barlera, R. Latini, L. Kjoller-Hansen, P. Sogaard, E. Christensen, L. Kober, and C. Torp-Pedersen A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction Eur J Heart Fail, February 1, 2007; 9(2): 129 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J de Kam, A. A Voors, F. Fici, D. J van Veldhuisen, and W. H van Gilst Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 161 - 168. [Abstract] [PDF] |
||||
![]() |
M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.E. Otterstad, M.G. St. John Sutton, G.S. Froeland, I. Holme, T. Skjaerpe, and C. Hall Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function Eur. Heart J., July 1, 2002; 23(13): 1011 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-J. de Kam, A. A. Voors, J. Brouwer, M. St John Sutton, and W. H. van Gilst Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model Eur J Heart Fail, June 1, 2002; 4(3): 277 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. M. van den Heuvel, P. H. J. M. Dunselman, T. Kingma, P. Verhorst, F. Boomsma, W. H. van Gilst, and D. J. van Veldhuisen Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade J. Am. Coll. Cardiol., February 1, 2001; 37(2): 470 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Willenheimer, E. Rydberg, L. Oberg, S. Juul-Moller, and L. Erhardt ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function Eur. Heart J., November 2, 1999; 20(22): 1647 - 1656. [Abstract] [PDF] |
||||
![]() |
M. J. Domanski, D. V. Exner, C. B. Borkowf, N. L. Geller, Y. Rosenberg, and M. A. Pfeffer Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials J. Am. Coll. Cardiol., March 1, 1999; 33(3): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Cody Comparing Angiotensin-Converting Enzyme Inhibitor Trial Results in Patients With Acute Myocardial Infarction Arch Intern Med, September 26, 1994; 154(18): 2029 - 2036. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1993 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |